Market Summary
USD7.36-0.28
Market Closed-3.66%
CDNA Stock Price
CDNA RSI Chart
CDNA Valuation
CDNA Price/Sales (Trailing)
CDNA Profitability
CDNA Fundamentals
CDNA Revenue
CDNA Earnings
Price Action
52 Week Range
6.2220.71
(Low)(High)
Last 7 days
-8.2%
Last 30 days
-15.7%
Last 90 days
-16.1%
Trailing 12 Months
-54.6%
CDNA Financial Health
CDNA Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for CDNA
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-07 | Jain Abhishek | sold (taxes) | -22,682 | 8.26 | -2,746 | chief financial officer |
2023-09-07 | Ronai Abraham | sold (taxes) | -12,100 | 8.26 | -1,465 | see remarks |
2023-09-06 | Jain Abhishek | sold (taxes) | -9,285 | 8.81 | -1,054 | chief financial officer |
2023-09-05 | Seeto Reginald | sold | -26,762 | 9.4935 | -2,819 | see remarks |
2023-08-14 | Seeto Reginald | sold | -5,122 | 8.8935 | -576 | see remarks |
2023-08-11 | Bickerstaff George | acquired | 99,064 | 5.09252 | 19,453 | - |
2023-08-07 | Seeto Reginald | sold (taxes) | -7,279 | 10.8 | -674 | see remarks |
2023-08-07 | Johnson Alexander L | sold (taxes) | -2,343 | 10.8 | -217 | chief business officer |
2023-08-02 | Seeto Reginald | sold | -31,987 | 11.3472 | -2,819 | see remarks |
2023-07-19 | Johnson Alexander L | sold (taxes) | -11,955 | 10.28 | -1,163 | chief business officer |
Which funds bought or sold CDNA recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-20 | BARCLAYS PLC | added | 4.56 | -41,000 | 1,436,000 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -2.17 | -54,405 | 548,497 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -14.73 | -40,564 | 155,431 | -% |
2023-08-16 | Nuveen Asset Management, LLC | reduced | -50.7 | -1,375,930 | 1,165,070 | -% |
2023-08-15 | Belpointe Asset Management LLC | sold off | -100 | -3,519 | - | -% |
2023-08-15 | ALLIANCEBERNSTEIN L.P. | added | 12.73 | 27,871 | 604,605 | -% |
2023-08-15 | Bullseye Asset Management LLC | unchanged | - | -96,000 | 1,273,000 | 0.64% |
2023-08-15 | GOLDMAN SACHS GROUP INC | added | 17.37 | 612,612 | 7,305,630 | -% |
2023-08-15 | LAZARD ASSET MANAGEMENT LLC | sold off | -100 | -18,000 | - | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | reduced | -0.45 | -55,990 | 698,700 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of CareDx
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Jul 07, 2023 | blackrock inc. | 10.1% | 5,439,512 | SC 13G/A | |
| Mar 13, 2023 | gagnon securities llc | 4.7% | 2,522,063 | SC 13G | |
| Feb 15, 2023 | arrowmark colorado holdings llc | 7.48% | 4,003,218 | SC 13G | |
| Feb 14, 2023 | bellevue asset management (uk) ltd. | 5.9% | 3,168,448 | SC 13G | |
| Feb 10, 2023 | ark investment management llc | 11.56% | 6,188,182 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.84% | 5,270,397 | SC 13G/A | |
| Feb 08, 2023 | invesco ltd. | 0.2% | 88,421 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 8.2% | 4,373,662 | SC 13G/A | |
| Jan 10, 2023 | state street corp | 10.74% | 5,747,244 | SC 13G/A | |
| Jan 10, 2023 | alger associates inc | 0.9% | 503,686 | SC 13G/A |
Recent SEC filings of CareDx
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 26, 2023 | 4 | Insider Trading | |
| Sep 26, 2023 | 8-K | Current Report | |
| Sep 25, 2023 | 8-K | Current Report | |
| Sep 11, 2023 | 4 | Insider Trading | |
| Sep 11, 2023 | 4 | Insider Trading | |
| Sep 08, 2023 | 4 | Insider Trading | |
| Sep 05, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 05, 2023 | 4 | Insider Trading | |
| Aug 14, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 14, 2023 | 4 | Insider Trading |
CDNA Fair Value
Loading...
Peers (Alternatives to CareDx)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
ABBV | 272.0B | 56.0B | 4.92% | 10.10% | 31.31 | 4.85 | -2.31% | -31.27% |
VRTX | 90.7B | 9.5B | 0.47% | 27.06% | 26.94 | 9.54 | 13.83% | 5.33% |
REGN | 89.1B | 12.7B | 0.25% | 21.32% | 20.72 | 7.03 | -10.94% | -24.40% |
INCY | 13.2B | 3.5B | -7.17% | -10.43% | 36.13 | 3.77 | 5.81% | -61.22% |
| MID-CAP | ||||||||
NTRA | 5.1B | 931.0M | -21.63% | 5.69% | -10.02 | 5.51 | 28.69% | 11.08% |
ARWR | 2.8B | 256.2M | -6.13% | -11.58% | -15.49 | 10.95 | 2.51% | -17.66% |
| SMALL-CAP | ||||||||
VCYT | 1.6B | 328.6M | -11.21% | 30.44% | -56.44 | 4.99 | 22.46% | 40.27% |
CSTL | 430.3M | 167.5M | -13.77% | -32.41% | -4.84 | 2.57 | 52.01% | -99.69% |
CDNA | 397.5M | 309.3M | -15.69% | -54.62% | -4.73 | 1.29 | -1.76% | -21.01% |
ORGO | 340.1M | 457.3M | -2.63% | -17.52% | 33.85 | 0.74 | -0.61% | -85.93% |
CELC | 212.5M | - | -2.68% | 7.78% | -4.34 | - | - | -59.74% |
NVTA | 164.1M | 493.9M | -30.95% | -74.20% | -0.21 | 0.33 | -1.39% | 74.28% |
OPGN | 1.5M | 2.8M | 28.48% | -44.24% | -0.04 | 0.54 | -31.25% | -41.90% |
CareDx News
Returns for CDNA
Cumulative Returns on CDNA
10.7%
7-Year Cumulative Returns
-23.2%
5-Year Cumulative Returns
-39.2%
3-Year Cumulative Returns
Risks for CDNA
What is the probability of a big loss on CDNA?
100%
Probability that CareDx stock will be more than 20% underwater in next one year
95%
Probability that CareDx stock will be more than 30% underwater in next one year.
57.7%
Probability that CareDx stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does CDNA drawdown profile look like?
Y-axis is the maximum loss one would have experienced if CareDx was unfortunately bought at previous high price.
Drawdowns
Financials for CareDx
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | -3.2% | 309,306,000 | 319,639,000 | 321,793,000 | 318,629,000 | 314,859,000 | 308,413,000 | 296,397,000 | 275,821,000 | 253,601,000 | 221,214,000 | 192,194,000 | 169,371,000 | 149,813,000 | 139,466,000 | 127,068,000 | 114,756,000 | 102,129,000 | 88,498,000 | 76,569,000 | 65,563,000 | 56,570,000 |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | 98,186,000 | 91,352,000 | 81,613,000 | 71,508,000 | 61,488,000 | 52,162,000 | 43,582,000 | 45,826,000 | 42,464,000 |
| Operating Expenses | -1.1% | 397,713,000 | 402,141,000 | 399,024,000 | 392,139,000 | 379,757,000 | 356,334,000 | 326,123,000 | 293,215,000 | 265,175,000 | 238,849,000 | 214,722,000 | 194,377,000 | 178,659,000 | 152,841,000 | 151,600,000 | 137,391,000 | 111,849,000 | 100,888,000 | 92,147,000 | 45,548,000 | 46,587,000 |
| S&GA Expenses | -5.5% | 90,790,000 | 96,110,000 | 96,027,000 | 93,183,000 | 92,292,000 | 84,941,000 | 77,245,000 | 72,552,000 | 65,052,000 | 57,587,000 | 53,858,000 | 47,994,000 | 45,182,000 | 43,692,000 | 38,894,000 | 34,381,000 | 29,294,000 | 24,510,000 | 21,670,000 | 18,977,000 | 16,261,000 |
| R&D Expenses | -2.6% | 90,466,000 | 92,865,000 | 90,388,000 | 88,864,000 | 85,997,000 | 82,401,000 | 76,525,000 | 67,804,000 | 60,839,000 | 54,932,000 | 48,941,000 | 44,562,000 | 40,609,000 | 35,110,000 | 30,711,000 | 25,547,000 | 20,894,000 | 16,760,000 | 14,514,000 | 13,760,000 | 12,851,000 |
| EBITDA | 100.0% | - | -67,788,000 | -64,631,000 | - | -60,459,000 | -41,331,000 | -23,290,000 | - | - | -7,230,000 | -12,734,000 | -14,288,000 | -14,340,000 | -15,930,000 | -18,402,000 | -16,270,000 | -34,214,000 | -40,823,000 | - | - | - |
| EBITDA Margin | 100.0% | - | -0.21 | -0.20 | - | -0.19 | -0.13 | -0.08 | - | - | -0.03 | -0.07 | -0.08 | -0.10 | -0.11 | -0.14 | -0.14 | -0.34 | -0.46 | - | - | - |
| Interest Expenses | - | - | - | 8,000 | - | - | - | 1,000 | - | - | - | 10,000 | - | - | - | 22,000 | - | - | - | 1,774,000 | - | - |
| Earnings Before Taxes | -4.1% | -83,474,000 | -80,199,000 | -76,234,000 | -75,130,000 | -70,517,000 | -50,798,000 | -32,088,000 | -18,722,000 | -9,716,000 | -14,577,000 | -19,750,000 | -21,045,000 | -20,754,000 | -21,933,000 | -23,947,000 | -23,060,000 | -40,558,000 | -46,934,000 | -48,215,000 | -76,622,000 | -70,827,000 |
| EBT Margin | 100.0% | - | -0.25 | -0.24 | -0.24 | -0.22 | -0.16 | -0.11 | -0.07 | -0.04 | -0.07 | -0.10 | -0.12 | -0.14 | -0.16 | -0.19 | - | - | - | - | - | - |
| Net Income | -4.0% | -83,970,000 | -80,714,000 | -76,613,000 | -74,435,000 | -69,393,000 | -49,623,000 | -30,662,000 | -18,026,000 | -8,947,000 | -13,578,000 | -18,714,000 | -19,976,000 | -18,971,000 | -20,260,000 | -21,968,000 | -20,946,000 | -39,103,000 | -45,318,000 | -46,756,000 | -74,672,000 | -68,970,000 |
| Net Income Margin | 100.0% | - | -0.25 | -0.24 | -0.23 | -0.22 | -0.16 | -0.10 | -0.07 | -0.04 | -0.06 | -0.10 | -0.12 | -0.13 | -0.15 | -0.17 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -3,100,000 | -25,239,000 | -28,258,000 | -20,797,000 | -17,413,333 | -29,575,333 | -26,560,333 | -21,219,333 | -5,432,000 | 24,537,667 | 16,273,667 | 15,441,000 | -2,798,333 | -4,699,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -2.5% | 515 | 528 | 543 | 545 | 541 | 547 | 567 | 563 | 557 | 541 | 369 | 354 | 345 | 157 | 152 | 145 | 143 | 128 | 131 | 91.00 | 80.00 |
| Current Assets | -2.9% | 361 | 371 | 388 | 388 | 404 | 411 | 433 | 445 | 441 | 439 | 273 | 259 | 252 | 66.00 | 72.00 | 68.00 | 68.00 | 78.00 | 81.00 | 42.00 | 31.00 |
| Cash Equivalents | 17.6% | 88.00 | 75.00 | 90.00 | 83.00 | 167 | 172 | 349 | 353 | 336 | 309 | 135 | 214 | 211 | 32.00 | 38.00 | 41.00 | 44.00 | 58.00 | 65.00 | 26.00 | 16.00 |
| Inventory | 4.6% | 19.00 | 18.00 | 19.00 | 18.00 | 19.00 | 18.00 | 17.00 | 19.00 | 15.00 | 14.00 | 10.00 | 10.00 | 9.00 | 7.00 | 6.00 | 6.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Net PPE | - | - | - | - | - | - | - | - | 19.00 | 14.00 | 11.00 | 11.00 | 10.00 | 7.00 | 6.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 3.00 | 2.00 |
| Goodwill | 0.1% | 40.00 | 40.00 | 38.00 | 38.00 | 37.00 | 37.00 | 37.00 | 26.00 | 26.00 | 26.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 23.00 | 12.00 | 12.00 | - | - |
| Liabilities | 1.3% | 110 | 108 | 112 | 108 | 98.00 | 89.00 | 101 | 91.00 | 78.00 | 70.00 | 91.00 | 85.00 | 84.00 | 55.00 | 53.00 | 47.00 | 50.00 | 32.00 | 35.00 | 47.00 | 51.00 |
| Current Liabilities | 3.7% | 74.00 | 72.00 | 76.00 | 70.00 | 78.00 | 67.00 | 77.00 | 70.00 | 56.00 | 46.00 | 69.00 | 62.00 | 57.00 | 28.00 | 35.00 | 31.00 | 29.00 | 16.00 | 20.00 | 16.00 | 14.00 |
| LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.00 | 13.00 |
| Shareholder's Equity | -3.5% | 405 | 420 | 431 | 437 | 444 | 458 | 466 | 472 | 480 | 472 | 278 | 269 | 261 | 101 | 99.00 | 98.00 | 93.00 | 96.00 | 96.00 | 44.00 | 29.00 |
| Retained Earnings | -5.2% | -509 | -484 | -460 | -441 | -424 | -402 | -383 | -367 | -355 | -353 | -352 | -349 | -346 | -339 | -333 | -329 | -327 | -319 | -311 | -308 | -288 |
| Additional Paid-In Capital | 1.2% | 924 | 912 | 899 | 887 | 875 | 865 | 854 | 843 | 838 | 828 | 632 | 622 | 612 | 448 | 438 | 432 | 425 | 420 | 412 | 356 | 321 |
| Shares Outstanding | 0.7% | 54.00 | 54.00 | 54.00 | 54.00 | 53.00 | 53.00 | 53.00 | 53.00 | 52.00 | 51.00 | 49.00 | 49.00 | 45.00 | 43.00 | 42.00 | 42.00 | 42.00 | 42.00 | 41.00 | 37.00 | 36.00 |
| Minority Interest | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cashflow (Last 12 Months)(In Thousands)
| Cashflow (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 109.0% | 278 | -3,100 | -25,239 | -28,258 | -20,797 | -7,132 | -19,294 | -16,279 | -11,454 | 2,856 | 33,431 | 25,167 | 20,565 | 43.00 | -2,769 | 312 | 106 | -5,356 | -4,007 | -8,155 | -10,774 |
| Share Based Compensation | 0.2% | 49,780 | 49,673 | 46,553 | 43,925 | 43,363 | 40,168 | 36,081 | 32,560 | 28,670 | 25,689 | 23,401 | 22,831 | 22,048 | 20,623 | 22,417 | 19,070 | 14,966 | 12,485 | 7,138 | 5,506 | 4,075 |
| Cashflow From Investing | 16.7% | -72,683 | -87,241 | -228,502 | -238,759 | -142,822 | -127,399 | 47,712 | -34,980 | -59,418 | -79,611 | -100,394 | -11,262 | -10,541 | -23,740 | -22,579 | -22,197 | -19,296 | -7,718 | -7,929 | -12,005 | -12,366 |
| Cashflow From Financing | 6.6% | -6,107 | -6,538 | -4,535 | -2,997 | -5,099 | -2,721 | 185,642 | 190,440 | 194,797 | 353,112 | 163,149 | 159,267 | 158,789 | -179 | -132 | 37,098 | 46,550 | 51,898 | 50,268 | 30,876 | 20,786 |
| Buy Backs | 9.7% | 1,514 | 1,380 | 642 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2,224 | - |
CDNA Income Statement
2023-06-30Condensed Consolidated Statements of Operations - USD ($) | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenue: | ||||
| Total revenue | $ 70,301,000 | $ 80,634,000 | $ 147,563,000 | $ 160,050,000 |
| Operating expenses: | ||||
| Research and development | 20,233,000 | 22,632,000 | 44,590,000 | 44,512,000 |
| Sales and marketing | 21,630,000 | 26,950,000 | 44,861,000 | 50,098,000 |
| General and administrative | 29,327,000 | 25,232,000 | 57,359,000 | 51,791,000 |
| Restructuring costs | 848,000 | 0 | 848,000 | 0 |
| Total operating expenses | 97,925,000 | 102,353,000 | 199,511,000 | 200,822,000 |
| Loss from operations | (27,624,000) | (21,719,000) | (51,948,000) | (40,772,000) |
| Other income (expense): | ||||
| Interest income, net | 2,871,000 | 478,000 | 5,537,000 | 667,000 |
| Change in estimated fair value of common stock warrant liability | 3,000 | 48,000 | 10,000 | 75,000 |
| Other expense, net | (271,000) | (553,000) | (2,245,000) | (1,376,000) |
| Total other income (expense) | 2,603,000 | (27,000) | 3,302,000 | (634,000) |
| Loss before income taxes | (25,021,000) | (21,746,000) | (48,646,000) | (41,406,000) |
| Income tax benefit (expense) | 68,000 | 49,000 | (56,000) | 61,000 |
| Net loss | $ (24,953,000) | $ (21,697,000) | $ (48,702,000) | $ (41,345,000) |
| Net loss per share | ||||
| Basic (in dollars per share) | $ (0.46) | $ (0.41) | $ (0.91) | $ (0.78) |
| Diluted (in dollars per share) | $ (0.46) | $ (0.41) | $ (0.91) | $ (0.78) |
| Weighted-average shares used to compute net loss per share: | ||||
| Basic (in shares) | 53,846,260 | 53,249,545 | 53,745,299 | 53,133,149 |
| Diluted (in shares) | 53,846,260 | 53,249,545 | 53,745,299 | 53,133,149 |
| Testing services revenue | ||||
| Revenue: | ||||
| Total revenue | $ 53,414,000 | $ 67,135,000 | $ 115,198,000 | $ 133,579,000 |
| Operating expenses: | ||||
| Cost of testing services, product, digital, and other | 15,324,000 | 18,230,000 | 30,620,000 | 35,858,000 |
| Product revenue | ||||
| Revenue: | ||||
| Total revenue | 7,876,000 | 6,714,000 | 14,737,000 | 13,502,000 |
| Operating expenses: | ||||
| Cost of testing services, product, digital, and other | 3,926,000 | 3,887,000 | 7,992,000 | 8,286,000 |
| Patient and digital solutions revenue | ||||
| Revenue: | ||||
| Total revenue | 9,011,000 | 6,785,000 | 17,628,000 | 12,969,000 |
| Operating expenses: | ||||
| Cost of testing services, product, digital, and other | $ 6,637,000 | $ 5,422,000 | $ 13,241,000 | $ 10,277,000 |
CDNA Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 87,786 | $ 89,921 |
| Marketable securities | 194,887 | 203,168 |
| Accounts receivable | 51,625 | 66,312 |
| Inventory | 18,840 | 19,232 |
| Prepaid and other current assets | 7,676 | 9,216 |
| Total current assets | 360,814 | 387,849 |
| Property and equipment, net | 36,084 | 35,529 |
| Operating leases right-of-use assets | 32,118 | 34,689 |
| Intangible assets, net | 43,529 | 43,051 |
| Goodwill | 39,655 | 37,523 |
| Restricted cash | 584 | 522 |
| Other assets | 2,036 | 3,828 |
| Total assets | 514,820 | 542,991 |
| Current liabilities: | ||
| Accounts payable | 9,880 | 9,942 |
| Accrued compensation | 14,441 | 16,902 |
| Accrued and other liabilities | 50,175 | 49,131 |
| Total current liabilities | 74,496 | 75,975 |
| Deferred tax liability | 51 | 0 |
| Common stock warrant liability | 0 | 32 |
| Deferred payments for intangible assets | 4,224 | 2,418 |
| Operating lease liability, less current portion | 30,589 | 33,406 |
| Other liabilities | 247 | 249 |
| Total liabilities | 109,607 | 112,080 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Preferred stock: $0.001 par value; 10,000,000 shares authorized at June 30, 2023 and December 31, 2022; no shares issued and outstanding at June 30, 2023 and December 31, 2022 | 0 | 0 |
| Common stock: $0.001 par value; 100,000,000 shares authorized at June 30, 2023 and December 31, 2022; 54,013,601 shares issued and outstanding at June 30, 2023; 53,583,301 shares issued and 53,533,250 shares outstanding at December 31, 2022 | 52 | 52 |
| Additional paid-in capital | 923,514 | 898,806 |
| Accumulated other comprehensive loss | (8,450) | (7,503) |
| Accumulated deficit | (509,903) | (460,444) |
| Total stockholders’ equity | 405,213 | 430,911 |
| Total liabilities and stockholders’ equity | $ 514,820 | $ 542,991 |
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.